These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
338 related articles for article (PubMed ID: 30820636)
1. Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD. Böcskei RM; Benczúr B; Losonczy G; Illyés M; Cziráki A; Müller V; Bohács A; Bikov A Lung; 2019 Apr; 197(2):189-197. PubMed ID: 30820636 [TBL] [Abstract][Full Text] [Related]
2. Elevated circulating PAI-1 levels are related to lung function decline, systemic inflammation, and small airway obstruction in chronic obstructive pulmonary disease. Wang H; Yang T; Li D; Wu Y; Zhang X; Pang C; Zhang J; Ying B; Wang T; Wen F Int J Chron Obstruct Pulmon Dis; 2016; 11():2369-2376. PubMed ID: 27713627 [TBL] [Abstract][Full Text] [Related]
3. The clinical value of suPAR in diagnosis and prediction for patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Huang Q; Xiong H; Shuai T; Wang Y; Zhang C; Zhang M; Zhu L; Lu J; Liu J Ther Adv Respir Dis; 2020; 14():1753466620938546. PubMed ID: 32643535 [TBL] [Abstract][Full Text] [Related]
4. Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD. Gumus A; Altintas N; Cinarka H; Kirbas A; Hazıroglu M; Karatas M; Sahin U Int J Chron Obstruct Pulmon Dis; 2015; 10():357-65. PubMed ID: 25709430 [TBL] [Abstract][Full Text] [Related]
5. The role of serum soluble urokinase-type plasminogen activator receptor in stable chronic obstructive pulmonary disease. Can Ü; Güzelant A; Yerlikaya FH; Yosunkaya Ş J Investig Med; 2014 Oct; 62(7):938-43. PubMed ID: 25127435 [TBL] [Abstract][Full Text] [Related]
6. Soluble urokinase-type plasminogen activator receptor as a measure of treatment response in acute exacerbation of COPD. AboEl-Magd GH; Mabrouk MM J Bras Pneumol; 2018; 44(1):36-41. PubMed ID: 29538541 [TBL] [Abstract][Full Text] [Related]